Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G 1
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Some tumor cells can be stimulated to differentiate and undergo terminal cell division and loss of tumorigenicity. The in vitro differentiation of murine erythroleukemia (MEL) cells is a dramatic example of tumor-cell reprogramming. We found that reentry of MEL cells into terminal differentiation is accompanied by an early transient decline in the activity of cyclin-dependant kinase (CDK) 2, followed by a decline of CDK6. Later, as cells undergo terminal arrest, CDK2 and CDK4 activities decline. By analyzing stable MEL-cell transfectants containing vectors directing inducible expression of specific CDK inhibitors, we show that only inhibitors that block the combination of CDK2 and CDK6 trigger differentiation. Inhibiting CDK2 and CDK4 does not cause differentiation. Importantly, we also show that reprogramming through inhibition of CDKs is restricted to G 1 phase of the cell cycle. The results imply that abrogation of normal cell-cycle controls in tumor cells contributes to their inability to differentiate fully and that restoration of such controls in G 1 can lead to resumption of differentiation and terminal cell division. The results also indicate that CDK4 and CDK6 are functionally distinct and support our hypothesis that the two CDKs regulate cell division at different stages of erythroid maturation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Differentiation induction of haematological malignant cells as well as normal HSC differentiation is mediated by a stochiometric ratio of transcription factors GATA-1 and PU.1 [41], which broadly determine lineage and cooperate with more specific transcription factors such as RAR receptor and CEBP family members [59, 93, 94].”
From PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis (2009) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Correlation of Terminal Cell Cycle Arrest of Skeletal Muscle with Induction of p21 by MyoD
Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., & Lassar, A. B. (1995) · Science · doi:10.1126/science.7863327 · Cited by 1,149
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119
Research works printed but not linked: 9
- D M Livingston Biochim Biophys Acta 1332, R25–R31 (1997).
- 10.1128/mcb.14.3.2066-2076.1994 · doi:10.1128/mcb.14.3.2066-2076.1994 · Paper page
- 10.1128/mcb.14.11.7195-7203.1994 · doi:10.1128/mcb.14.11.7195-7203.1994 · Paper page
- 10.1182/blood.V96.8.2755 · doi:10.1182/blood.v96.8.2755
- J Wang, K Guo, K N Wills, K Walsh Cancer Res 57, 351–354 (1997).
- T Akagi, H Ono, K Shimotohno Oncogene 13, 399–405 (1996).
- M Chilosi, C Doglioni, Z Yan, M Lestani, F Menestrina, C Sorio, A Benedetti, F Vinante, G Pizzolo, G Inghirami Am J Pathol 152, 209–217 (1998).
- M Vairapandi, A G Balliet, A J Fornace, B Hoffman, D A Liebermann Oncogene 12, 2579–2594 (1996).
- H R Lee, T H Chang, M J Tebalt, A M Senderowicz, E Szabo Int J Oncol 15, 161–166 (1999).
Cited by
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
“(Matushansky et al., 2000).”
Ruijtenberg, S., & van den Heuvel, S. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120925 · Cited by 553
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
“Third, in some instances, inhibition of CDKs contributes to cell differentiation [ 15 ].”
BackgroundRoscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Oh, H., Taffet, G. E., Youker, K. A., Entman, M. L., Overbeek, P. A., Michael, L. H., & Schneider, M. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191169098 · Cited by 289
Christian, S., Merz, C., Evans, L., Gradl, S., Seidel, H., Friberg, A., Eheim, A., Lejeune, P., Brzezinka, K., Zimmermann, K., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0461-5 · Cited by 241
Coordinating cell proliferation and differentiation
Zhu, L., & Skoultchi, A. I. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00162-3 · Cited by 246
Self-citationRegulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma
Pierson, J., Hostager, B., Fan, R., & Vibhakar, R. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9624-3 · Cited by 233
“For example, over-expression of inhibitor resistant CDK6 prevents murine erythroid leukemia cells from undergoing differentiation upon stimulation [32].”
BackgroundPark, M.-T., & Lee, S.-J. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.060 · Cited by 200
“Third, in some instances, the inhibition of CDKs contributes to the cell differentiation (Matushansky et al., 2000).”
BackgroundThe ISWI ATPase Snf2h is required for early mouse development
Stopka, T., & Skoultchi, A. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336105100 · Cited by 203
Self-citationErythropoiesis: Model systems, molecular regulators, and developmental programs
Tsiftsoglou, A. S., Vizirianakis, I. S., & Strouboulis, J. (2009) · IUBMB Life · doi:10.1002/iub.226 · Cited by 199
New insights into erythropoiesis
Koury, M. J., Sawyer, S. T., & Brandt, S. J. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200203000-00002 · Cited by 177
Mechanisms involved in the induced differentiation of leukemia cells
Tsiftsoglou, A. S., Pappas, I. S., & Vizirianakis, I. S. (2003) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.09.002 · Cited by 181
Feng, L., Xie, Y., Zhang, H., & Wu, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-9823-1 · Cited by 134
“prevents murine erythroid leukemia cells from undergoing differentiation upon stimulation [6].”
BackgroundCell cycle regulators and hematopoiesis
Steinman, R. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205325 · Cited by 128
“In a provocative study in erythroleukemia cells, Matushansky et al. (2000b) demonstrated that transient exposure to a cdk2 inhibitor (either p21 or roscovitine) followed by arti®cial p16 induction led to terminal di erentiation.”
BackgroundResultInfluentialEKLF/KLF1-regulated cell cycle exit is essential for erythroblast enucleation
Gnanapragasam, M. N., McGrath, K. E., Catherman, S. C., Li, X., Palis, J., & Bieker, J. J. (2016) · Blood · doi:10.1182/blood-2016-03-706671 · Cited by 104
Muñoz-Alonso, M. J., Acosta, J. C., Richard, C., Delgado, M. D., Sedivy, J. M., & León, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500758200 · Cited by 89
Beyond the cell cycle: A new role for Cdk6 in differentiation
Grossel, M. J., & Hinds, P. W. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20712 · Cited by 84
“One of the earliest reports of a role for cdk6 in differentiation was published in 2000 [Matushansky et al., 2000].”
BackgroundHandschuh, L., Kaźmierczak, M., Milewski, M., ralski, M. G. ⁄., Łuczak, M., Wojtaszewska, M. L., Uszczyńska-Ratajczak, B., Lewandowski, K. C., Komarnicki, M. A., & Figlerowicz, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4233 · Cited by 96
Dorsey, J. F., Cunnick, J. M., Mane, S., & Wu, J. (2002) · Blood · doi:10.1182/blood.v99.4.1388 · Cited by 83
Matushansky, I., Radparvar, F., & Skoultchi, A. I. (2003) · Oncogene · doi:10.1038/sj.onc.1206484 · Cited by 88
“The late decline in CDK2 and CDK4 activities is not because of a decline in the amounts of the catalytic subunit of the enzymes (Figure 1c) nor in the amounts of the cyclin regulatory subunits (Matushansky et al., 2000a).”
BackgroundMethodInfluentialSelf-citationGupta, P., Gurudutta, G. U., Saluja, D., & Tripathi, R. P. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00757.x · Cited by 74
“1 [41], which broadly determine lineage and cooperate with more specific transcription factors such as RAR receptor and CEBP family members [59, 93, 94].”
BackgroundCdk1, Plks, Auroras, and Neks: The Mitotic Bodyguards
Salaün, P., Rannou, Y., & Prigent, C. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_4 · Cited by 71
“78 Matushansky, I. et al. (2000) Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1.”
BackgroundThe A‐type cyclins and the meiotic cell cycle in mammalian male germ cells
Wolgemuth, D. J., Lele, K. M., Jobanputra, V., & Salazar, G. (2004) · International Journal of Andrology · doi:10.1111/j.1365-2605.2004.00480.x · Cited by 57
Cpeb4-Mediated Translational Regulatory Circuitry Controls Terminal Erythroid Differentiation
Hu, W., Yuan, B., & Lodish, H. F. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.07.008 · Cited by 51
“First, downregulation of Cdk6 is known to be required for terminal erythroid differentiation; while constitutive expression of Cdk6 blocks this differentiation process (Matushansky et al., 2000, 2003).”
BackgroundTargeted therapies in myeloid leukemia
John, A. M., Thomas, N. S. B., Mufti, G. J., & Padua, R. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.006 · Cited by 62
“[219] Matushansky I, Radparvar F, Skoultchi AI.”
BackgroundNussinov, R., Yavuz, B. R., Arici, M. K., Demirel, H. C., Zhang, M., Liu, Y., Tsai, C., Jang, H., & Tunçbağ, N. (2023) · Biophysical Reviews · doi:10.1007/s12551-023-01054-9 · Cited by 49
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
Winteringham, L. N., Kobelke, S., Williams, J. H., Ingley, E., & Klinken, S. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207661 · Cited by 47
“Several different models examining erythroid maturation have consistently shown an increase in p27Kip1 (Panzenbock et al., 1998; Hsieh et al., 2000; Matushansky et al., 2000a,b; Tamir et al., 2000; Jacobs-Helber et al., 2002; Bouscary et al., 2003).”
BackgroundAdipogenesis licensing and execution are disparately linked to cell proliferation
Guo, W., Zhang, K., Tu, K., Li, Y., Zhu, L., Xiao, H., Yang, Y., & Wu, J. (2008) · Cell Research · doi:10.1038/cr.2008.319 · Cited by 50
Ericson, K. K., Krull, D., Slomiany, P., & Grossel, M. J. (2003) · PubMed · Cited by 46
GATA-1 directly regulates p21 gene expression during erythroid differentiation
Papetti, M., Wontakal, S. N., Stopka, T., & Skoultchi, A. I. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11602 · Cited by 54
“Among four CDKIs tested (p15, p16, p21 and p27), only p21 was sufficient to reprogram the leukemia cells to terminal differentiation.(19) The differentiation program induced by p21 in MEL cells is similar to that induced by GATA-1/ER in these cells, including synthesis of hemoglobin, morphological differentiation and…”
BackgroundInfluentialSelf-citationReversal of tumorigenicity and the block to differentiation in erythroleukemia cells by GATA-1.
Choe, K. S., Radparvar, F., Matushansky, I., Rekhtman, N., Han, X., & Skoultchi, A. I. (2003) · PubMed · Cited by 51
Self-citationYang, H., Hui, H., Wang, Q., Li, H., Zhao, K., Zhou, Y., Zhu, Y., Wang, X., You, Q., Guo, Q., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2340 · Cited by 39
“It is reported that GATA-1 binds to the promoter of p21 and activates its transcription[29-32].”
Backgroundp16INK4a induces differentiation and apoptosis in erythroid lineage cells
Minami, R., Muta, K., Umemura, T., Motomura, S., Abe, Y., Nishimura, J., & Nawata, H. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00040-7 · Cited by 41
“Another study demonstrated that murine erythroleukemia (MEL) cells expressed p16, which decreased during erythroid differentiation [23].”
BackgroundChoe, K. S., Ujhelly, O., Wontakal, S. N., & Skoultchi, A. I. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077727 · Cited by 36
Self-citationMolecular targets and the treatment of myeloid leukemia
Ikeda, A. K., Shankar, D. B., Watanabe, M., Tamanoi, F., Moore, T. B., & Sakamoto, K. M. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.03.011 · Cited by 33
Randle, S. J., Nelson, D. E., Patel, S. P., & Laman, H. (2015) · The Journal of Pathology · doi:10.1002/path.4571 · Cited by 35
“However, it has been proposed that CDK6 down-regulation alone is not sufficient and that CDK2 inhibition is necessary [28,29], which our experiments support.”
BackgroundCdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis
Rodríguez, E., Quereda, V., Bellutti, F., Prchal‐Murphy, M., Partida, D., Eguren, M., Kollmann, K., de Cedrón, M. G., Dubus, P. R., Cañamero, M., et al. (2014) · Blood · doi:10.1182/blood-2014-02-555292 · Cited by 38
A proapoptotic function of p21 in differentiating granulocytes
Ghanem, L. R., & Steinman, R. A. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.03.018 · Cited by 32
Yellajoshyula, D., & Brown, D. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606478103 · Cited by 29
Expression of cdk6 in head and neck squamous cell carcinoma
Poomsawat, S., Sanguansin, S., Punyasingh, J., Vejchapipat, P., & Punyarit, P. (2015) · Clinical Oral Investigations · doi:10.1007/s00784-015-1482-8 · Cited by 28
Rosato, R. R., Almenara, J. A., Maggio, S. C., Atadja, P. W., Craig, R. W., Vrana, J. A., Dent, P., & Grant, S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0157 · Cited by 34
“(49) observed that, whereas sequential inactivation of CDK4 by induction of the CDKI p16 followed by CDK2 inhibition by roscovitine led to maturation of MEL cells, the reverse sequence resulted in apoptosis.”
BackgroundGagrica, S., Brookes, S., Anderton, E., Rowe, J., & Peters, G. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2552 · Cited by 28
“Whereas p16 is primarily involved in the implementation of senescence in response to diverse forms of stress, most studies link p18 with differentiation and suggest that p18 and CDK6 are partners in crime (3, 4, 6, 50-53).”
Claudin 13, a Member of the Claudin Family Regulated in Mouse Stress Induced Erythropoiesis
Thompson, P. D., Tipney, H., Brass, A., Noyes, H. A., Kemp, S., Naessens, J., & Tassabehji, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012667 · Cited by 30
“. There is evidence that CDKN2D contributes to differentiation of a model system of transformed erythroid precursors, murine erythroleukaemia (MEL) cells, by inhibition of CDK6”
BackgroundEstefanía, M. M., Ganier, O., Hernández, P., Schvartzman, J. B., Méchali, M., & Krimer, D. B. (2012) · Scientific Reports · doi:10.1038/srep00279 · Cited by 26
“Some observations indicate that MEL phenotypic differentiation and terminal cell division, however, are not necessarily couple”
BackgroundMatragkou, C., Papachristou, E., Tezias, S. S., Tsiftsoglou, A. S., Choli‐Papadopoulou, T., & Vizirianakis, I. S. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21722 · Cited by 25
“…(serine/threonine protein kinases) (CDK2, CDK4, and CDK6) play crucial role in cell cycle regulation of eukaryotic cells and that CDKs are involved in the initiation of commitment of MEL cells into terminal maturation [Hsieh et al., 2000; Matushansky et al., 2000a,b, 2003; Zhu and Skoultchi, 2001].”
BackgroundResultMoore, J. C., Sumerel, J. L., Schnackenberg, B. J., Nichols, J. A., Wikramanayake, A. H., Wessel, G. M., & Marzluff, W. F. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4863-4875.2002 · Cited by 24
Mouse Models of Cell Cycle Regulators: New Paradigms
Aleem, E. A., & Kaldis, P. (2006) · Springer eBooks · doi:10.1007/400_023 · Cited by 25
Mitochondrial concept of leukemogenesis: key role of oxygen-peroxide effects
Lyu, B. N., Ismailov, S. B., Ismailov, B. I., & Lyu, M. B. (2008) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-5-23 · Cited by 22
Papetti, M., & Skoultchi, A. I. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0145 · Cited by 26
“1 siRNA treatment, we prepared cells at various stages of the cell cycle by centrifugal elutriation, a method that separates cells by their size, which correlates with their position in the cell cycle (34, 35).”
BackgroundMethodResultInfluentialSelf-citationNagasawa, M., Gelfand, E. W., & Lucas, J. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204396 · Cited by 26
“Matushansky et al. (2000a) showed that whereas ectopic over-expression of a combination of cdk2 and cdk4 could extend the proliferation of di erentiating mouse erythroleukemia cells, cdk2 combined with cdk6 could not.”
BackgroundGarcía-Sacristán, A., Fernández-Nestosa, M. J., Hernández, P., Schvartzman, J. B., & Krimer, D. B. (2005) · Cell Research · doi:10.1038/sj.cr.7290319 · Cited by 19
Marion, W., Boettcher, S., Ruiz-Torres, S., Lummertz da Rocha, E., Lundin, V., Morris, V., Chou, S. S., Zhao, A. M., Kubaczka, C., Aumais, O., et al. (2020) · PubMed Central · doi:10.5167/uzh-190916 · Cited by 21
Li, H., Hui, H., Xu, J., Yang, H., Zhang, X., Liu, X., Zhou, Y., Li, Z., Guo, Q., & Lu, N. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1552-3 · Cited by 18
Cailleteau, C., Micallef, L., Lepage, C., Cardot, P. J. P., Beneytout, J., Liagre, B., & Battu, S. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4062-4 · Cited by 17
“The abrogation of normal cell-cycle controls in tumor cells contributes to their inability to differentiate fully, and the restoration of such controls in G1 can lead to the resumption of differentiation and terminal cell division in murine erythroleukemia cells (MEL cell line) [54].”
BackgroundSchmitz, N. M. R., Leibundgut, K., & Hirt, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403900 · Cited by 17
CDK6 binds and promotes the degradation of the EYA2 protein
Kohrt, D., Crary, J. I., Zimmer, M., Patrick, A. N., Ford, H. L., Hinds, P. W., & Grossel, M. J. (2013) · Cell Cycle · doi:10.4161/cc.26755 · Cited by 16
Reprogramming of mesenchymal stem cells by oncogenes
Eid, J. E., & Garcia, C. B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.005 · Cited by 23
The shifting shape and functional specializations of the cell cycle during lineage development
Hwang, Y., Hidalgo, D., & Socolovsky, M. (2020) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1504 · Cited by 18
Schmitz, N., Hirt, A., Aebi, M., & Leibundgut, K. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051137 · Cited by 17
Kuo, T. C., Chavarría‐Smith, J., Huang, D. Y., & Schlissel, M. S. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01349-10 · Cited by 15
“Most recently, a role for CDK6 but not CDK4 was observed in the differentiation of a variety of cell types (7, 26, 27).”
BackgroundNishigaki, K., Hanson, C. A., Ohashi, T., Spadaccini, A., & Ruscetti, S. (2006) · Journal of Virology · doi:10.1128/jvi.02651-05 · Cited by 19
“Inhibition of cyclin-dependent kinases by activation of CDK inhibitors appears to be essential for the induction of cell cycle arrest and the initiation of terminal erythroid differentiation (25, 26), and roles for STAT proteins in negatively regulating the cell cycle have been demonstrated.”
BackgroundAnimal Models for Studying the In Vivo Functions of Cell Cycle CDKs
Risal, S., Adhikari, D., & Liu, K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2926-9_13 · Cited by 17
Vizirianakis, I. S., Papachristou, E., Andreadis, P., ZOPOUNIDOU, E., Matragkou, C., & Tsiftsoglou, A. S. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3017 · Cited by 14
Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
Mills, J. E., Hricik, T., Siddiqi, S., & Matushansky, I. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0724 · Cited by 13
“All protein gels were run as sequential immunoprecipitation-immunoblotting (IP-IB), using the same antibody for both steps to increase sensitivity of detection as previously described (29).”
MethodSelf-citationp19INK4d: More than Just a Cyclin-Dependent Kinase Inhibitor
Han, X., Kuang, Y., Chen, H., Liu, T., Zhang, J., & Liu, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190809161901 · Cited by 13
Kroll, S. L., Baus, D., & Hensold, J. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m109577200 · Cited by 11
Siatecka, M., Soni, S., Planutis, A., & Bieker, J. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610246 · Cited by 9
“Stable DS19MEL cells, which express the reverse tetracycline-controlled transactivator (rtTA) (16), were cotransfected with plasmid pTRE2 (containing Flag-PIAS3-WT or FlagPIAS3 LXXLL) and with pBabe-puro in a 10:1 ratio using Lipofectamine LTX Plus reagent (Life Technologies) according to the manufacturer’s protocol.”
Methodp19Ink4d and p18Ink4c cyclin‐dependent kinase inhibitors in the male reproductive axis
Buchold, G. M., Magyar, P. L., Arumugam, R., Lee, M., & O’Brien, D. A. (2007) · Molecular Reproduction and Development · doi:10.1002/mrd.20716 · Cited by 8
“Matushansky et al. (2000) have demonstrated CDK6- and CDK4dominated phases of erythroid differentiation, similar to what we have seen in germ cells.”
ResultDevelopmental pathways of myeloid-derived suppressor cells in neoplasia
Abrams, S. I. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104261 · Cited by 9
Papagiannopoulos, C. I., Theodoroula, N. F., Kyritsis, K., Akrivou, M. G., Kosmidou, M. S., Tsouderou, K., Grigoriadis, N., & Vizirianakis, I. S. (2021) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-020-00132-3 · Cited by 6
Thomas, N. S. B. (2004) · CRC Press eBooks · doi:10.1201/b14440-5 · Cited by 5
p27Kip1 regulates γ-globin production
Balbin-Cuesta, G., Drysdale, C. M., Kerpet, C., Yu, L., Myers, G., Lin, Z., McGee, B. M., Friedman, A. D., Liu, X., Singh, S. A., et al. (2025) · Blood · doi:10.1182/blood.2025028895 · Cited by 5
Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
Park, J. H., Park, H., Kim, K. H., Kim, J.-S., Choi, I. S., Roh, E. Y., Kim, J. E., & Chang, M. S. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e1 · Cited by 5
“Leukemia involves loss of normal proliferation and interruption in the complete differentiation into mature cells [11].”
BackgroundUsing Natural Products to Unravel Cell Biology
Gough, J. D., & Crews, C. M. (2007) · Chemical biology · doi:10.1002/9783527619375.ch2b · Cited by 3
Wu, N., Li, R., Meng, Z., Nie, M., Chen, Q., He, B., Deng, Z., & Yin, L. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3910 · Cited by 2
Involvement of CREB3L1 in erythropoiesis induced by JAK2 exon 12 mutation
Okuda, M., Araki, M., Marchi, F. D., Morishita, S., Imai, M., Fukada, H., Ando, M., & Komatsu, N. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104636 · Cited by 1
Pharmacological and analytical studies of the cyclin dependent kinase inhibitors
Sallam, H. (2009) · Figshare · Cited by 2
Wu, N., Li, R., Meng, Z., Nie, M., Chen, Q., He, B., Deng, Z., & Yin, L. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4817 · Cited by 1
The Role and Regulation of p21 in Myelopoiesis
Ghanem, L. R. (2005) · D-Scholarship@Pitt (University of Pittsburgh)
Short Communication: Adhesion Pathways Utilized by HIV-Infected Lymphocytes
Chow, Y., Liu, L., Schwartz, B. R., Harlan, J. M., & Schnapp, L. M. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0262
Rational targeting in acute promyelocytic leukemia.
Papanikolaou, N. A. (2010) · PubMed · Cited by 2
The regulation of cell cycle exit during Caenorhabditis elegans vulva formation
Nieuwland, J. (2020) · Utrecht University Repository (Utrecht University)
Metadata
- Authors
- Matushansky, I., Radparvar, F., & Skoultchi, A. I.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-12-12
- Volume
- 97
- Issue
- 26
- Pages
- 14317-14322
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18916
- OpenAlex
- W2162429172
- Cited by
- 84
- References
- 48
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 4 · 2017: 2 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 2
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (T32AG000194)
- National Cancer Institute (P30CA013330)
- National Institute of General Medical Sciences (5T32GM07288-25, T32GM007288)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- leukemia cell differentiation, terminal differentiation, cyclin-dependent kinases, CDK2, CDK4, CDK6, murine erythroleukemia cells, G1 phase, cell cycle regulation, cyclin-dependent kinase inhibitors, erythroid maturation, tumor reprogramming
- MeSH terms
- Animals, Cell Cycle, Cell Differentiation, Leukemia, Erythroblastic, Acute, Humans, Proto-Oncogene Proteins, Tumor Cells, Cultured, G1 Phase, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.